Diligence memo · auto-generated · as of July 2, 2026
Natrogen Therapeutics International, Inc.
Natrogen Therapeutics International, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Natrogen Therapeutics International, Inc. operates in Pharmaceuticals, based in New York.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Natrogen Therapeutics International, Inc. has raised $3.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.4M on 2010-03-01.
Most recent recorded round closed around 2010-03-01.
Valuation (modeled)modeled
Provath models Natrogen Therapeutics International, Inc. at approximately $55M (range $1.1M–$430M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.92× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era. Within the normal band (92% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 16.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 5.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 35% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.